[
  {
    "ts": null,
    "headline": "McKesson (MCK) Upgraded to Strong Buy: Here's What You Should Know",
    "summary": "McKesson (MCK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
    "url": "https://finnhub.io/api/news?id=2297152c53ec1f7139b3eb21ce177d445a2d5f1a5580df7135ae1ef529f4b49b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761667204,
      "headline": "McKesson (MCK) Upgraded to Strong Buy: Here's What You Should Know",
      "id": 137243803,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCK",
      "source": "Yahoo",
      "summary": "McKesson (MCK) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.",
      "url": "https://finnhub.io/api/news?id=2297152c53ec1f7139b3eb21ce177d445a2d5f1a5580df7135ae1ef529f4b49b"
    }
  },
  {
    "ts": null,
    "headline": "This ‘Strong Buy’ Healthcare Stock Just Hit New All-Time Highs",
    "summary": "McKesson (MCK) is trading at new all-time highs and has strong technical momentum. MCK has a 100% “Buy” opinion from Barchart. Shares are up nearly 60% over the past year. Analyst sentiment is overwhelmingly positive, with multiple “Strong Buy” ratings and price targets up to $984, despite some valuation concerns....",
    "url": "https://finnhub.io/api/news?id=c544aa17eea08590522d68e6ddd8ba3b47543d4052fdc1a33b9ddce285b1e29a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761665103,
      "headline": "This ‘Strong Buy’ Healthcare Stock Just Hit New All-Time Highs",
      "id": 137243804,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCK",
      "source": "Yahoo",
      "summary": "McKesson (MCK) is trading at new all-time highs and has strong technical momentum. MCK has a 100% “Buy” opinion from Barchart. Shares are up nearly 60% over the past year. Analyst sentiment is overwhelmingly positive, with multiple “Strong Buy” ratings and price targets up to $984, despite some valuation concerns....",
      "url": "https://finnhub.io/api/news?id=c544aa17eea08590522d68e6ddd8ba3b47543d4052fdc1a33b9ddce285b1e29a"
    }
  },
  {
    "ts": null,
    "headline": "Baxter Q3 Preview: Can Core Segments Deliver Another Solid Quarter?",
    "summary": "Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.",
    "url": "https://finnhub.io/api/news?id=006965ff5fdd985b8ad03a6320026a3af6de0ab707c616354987a6c27f96c3d9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761657360,
      "headline": "Baxter Q3 Preview: Can Core Segments Deliver Another Solid Quarter?",
      "id": 137238357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCK",
      "source": "Yahoo",
      "summary": "Baxter's Q3 results are expected to show steady revenue growth led by Advanced Surgery and Drug Compounding, though IV fluid and anesthesia softness may weigh on EPS.",
      "url": "https://finnhub.io/api/news?id=006965ff5fdd985b8ad03a6320026a3af6de0ab707c616354987a6c27f96c3d9"
    }
  },
  {
    "ts": null,
    "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
    "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
    "url": "https://finnhub.io/api/news?id=8762ee7135901f01cd2a0945faf3ced487119340a13032101342537c384cec6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761656403,
      "headline": "These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar",
      "id": 137238378,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCK",
      "source": "Yahoo",
      "summary": "Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.",
      "url": "https://finnhub.io/api/news?id=8762ee7135901f01cd2a0945faf3ced487119340a13032101342537c384cec6f"
    }
  },
  {
    "ts": null,
    "headline": "VSee Awarded US Department of Health & Human Services FedRAMP High ATO",
    "summary": "SAN JOSE, CALIFORNIA / ACCESS Newswire / October 28, 2025 / VSee Health, Inc.(Nasdaq:VSEE) (the \"Company\"), announced it has received its Authority to Operate (ATO) at the FedRAMP High level from the U.S. Department of Health and Human Services (HHS). ...",
    "url": "https://finnhub.io/api/news?id=42377fe359a87823219c5dc089165b504cd34102347006d2862bf7434f228ef8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761654000,
      "headline": "VSee Awarded US Department of Health & Human Services FedRAMP High ATO",
      "id": 137238015,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCK",
      "source": "Yahoo",
      "summary": "SAN JOSE, CALIFORNIA / ACCESS Newswire / October 28, 2025 / VSee Health, Inc.(Nasdaq:VSEE) (the \"Company\"), announced it has received its Authority to Operate (ATO) at the FedRAMP High level from the U.S. Department of Health and Human Services (HHS). ...",
      "url": "https://finnhub.io/api/news?id=42377fe359a87823219c5dc089165b504cd34102347006d2862bf7434f228ef8"
    }
  },
  {
    "ts": null,
    "headline": "United State Cell and Gene Therapy Third-Party Logistics Market Analysis Report 2025-2033: Expansion Fueled by Rising R&D Expenditure, Regulatory Complexity, & Strong Demand from Major Biopharma Hubs",
    "summary": "The U.S. Cell and Gene Therapy Third-Party Logistics (3PL) Market is anticipated to surge from US$ 2.61 billion in 2024 to US$ 5.88 billion by 2033, maintaining a CAGR of 9.46% from 2025 to 2033. Key growth drivers include increased therapy adoption, specialized logistics needs, and expanding biopharmaceutical collaborations. Regulatory demands, cold chain technology adoption, and challenges such as logistics costs and workforce expertise underscore the market's evolution. States like California",
    "url": "https://finnhub.io/api/news?id=eb8a02abf93aa446f2a038731d8e04b6c8187eeb84d1066ec4654dd43b6166e4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761653100,
      "headline": "United State Cell and Gene Therapy Third-Party Logistics Market Analysis Report 2025-2033: Expansion Fueled by Rising R&D Expenditure, Regulatory Complexity, & Strong Demand from Major Biopharma Hubs",
      "id": 137238016,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MCK",
      "source": "Yahoo",
      "summary": "The U.S. Cell and Gene Therapy Third-Party Logistics (3PL) Market is anticipated to surge from US$ 2.61 billion in 2024 to US$ 5.88 billion by 2033, maintaining a CAGR of 9.46% from 2025 to 2033. Key growth drivers include increased therapy adoption, specialized logistics needs, and expanding biopharmaceutical collaborations. Regulatory demands, cold chain technology adoption, and challenges such as logistics costs and workforce expertise underscore the market's evolution. States like California",
      "url": "https://finnhub.io/api/news?id=eb8a02abf93aa446f2a038731d8e04b6c8187eeb84d1066ec4654dd43b6166e4"
    }
  }
]